Successful restoration of spermatogenesis following gender-affirming hormone therapy in transgender women.
Cell Rep Med
; 4(1): 100858, 2023 01 17.
Article
em En
| MEDLINE
| ID: mdl-36652919
ABSTRACT
Increasing numbers of transgender individuals are presenting for gender-affirming medical care. For trans women, gender-affirming hormone therapy (GAHT) promotes feminization but also inhibits spermatogenesis. There is a common untested assumption that this inhibition is permanent, resulting in infertility. In this longitudinal study, we report the recovery of viable spermatozoa in nine trans women who stopped GAHT for reproductive purposes. Our preliminary findings suggest that the negative impact of GAHT on spermatogenesis can be reversed, casting doubt on previous claims that GAHT in trans women inevitably leads to permanent infertility. Larger studies are needed to confirm our findings, which have implications not only for fertility counseling and the reproductive options of transgender individuals but also efforts to restrict access to GAHT based on fertility grounds.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pessoas Transgênero
/
Infertilidade
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article